Omega-3 fatty acids for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Oliver, Colleen ^a   Watson, Helen ^b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL FATTY ACID; LEUKOTRIENE B4; LEUKOTRIENE B5; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; PLACEBO;

ADVERSE EVENT; CELL MEMBRANE; CYSTIC FIBROSIS; HUMAN; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NEUTROPHIL; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SHWACHMAN SCORE; SIDE EFFECT; SPUTUM; STOMACH PAIN; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; DIET SUPPLEMENTATION; DIET THERAPY;

CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84900759456     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002201.pub4     Document Type: Review

References (54)

1. Henderson WR. Omega-3 supplementation in cystic fibrosis [abstract]. Proceedings of the 6th North American Cystic Fibrosis Conference; 1992 1992;Abstract Edition:S21.2.
2. Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Becker JU, Ramsey B. Absorption of omega (w) -3 fatty acids in CF patients [abstract]. Pediatric Pulmonology 1992;Abstract Edition 2:311.
3. Henderson WR Jr, Astley SJ, McCready MT, Kushmerick P, Casey S, Becker JW, et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics 1994;124(3):400-8.
4. Keen C, Olin A, Eriksson S, Ekman A, Lindblad A, Basu S, et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2010;50(5):537-44.
5. Keen C, Olin A, Eriksson S, Lindblad A, Ekman A, Basu S, Beerman C, Strandvik B. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s.
6. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993;342(8869):465-9.
7. Lawrence R, Sorrell T. Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis [abstract]. Australian and New Zealand Journal of Medicine 1993;23:442.
8. Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Boulat O, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo-controlled trial. Clinical Nutrition 2006;25(3):418-27.
9. Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Roule M. Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis 2005;4:S88.
10. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzu G, BiffiA, et al. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 2013;88(2):163-9. [CFGD Register: GN118d; CRS-ID: 5500100000011192]
11. Alicandro G, Gagliardini R, Rise P, Santini B, BiffiA, Tirelli S, et al. Oral DHA supplementation in children with CF: a randomized placebo-controlled study [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:394, Abstract no: 499. [CFGD Register: GN118c; CRS-ID: 5500100000011191]
12. Alicandro G, Gagliardini R, Santini B, Rise P, BiffiA, Tirelli AS, et al. Oral DHA supplementation in children with cystic fibrosis: a randomized placebo-controlled study [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S74, Abstract no: 290. [CFGD Register: GN118b; CRS-ID: 5500100000011190]
13. Colombo C, Dacco V, Santini B, Garliardini R, Loi S, Casartelli M, et al. DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:427. [CFGD Register: GN118a]
14. Christophe A, Robberecht E, Franckx H. Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis. 11th International Cystic Fibrosis Congress. 1992.
15. Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 1996;12(5):334-9.
16. Manner T, Guida L, Katz DP, Askanazi J, Schlotzer E, Wiesse S. Parenteral fish oil administration in patients with cystic fibrosis [abstract]. Clinical Nutrition 1992;Abstract Edition(11):40.
17. Manner T, Katz DP, Askanazi J, Schlotzer E, Furst P. Parenteral fish oil administration in patients with cystic fibrosis [abstract]. Proceedings of the 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition). 1993:440.
18. Koletzko B, Tuxen-Mengedoht M, Muller I, Demmelmair H, Stern M, Steffan J. Polyunsaturated fatty acids improve outcome of cystic fibrosis patients [abstract]. Proceedings of the 13th International Cystic Fibrosis Conference; 2000 June 4-8; Stockholm. 2000:78.
19. Tuxen-Mengedoht M, Koletzko B, Demmelmair H, Knapp V, Stern M. Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial [abstract]. Clinical Nutrition 1999;18(Suppl 1):54.
20. Tuxen-Mengedoht M, Koletzko B, Muller I, Demmelmair H, Knapp V, Stern M, et al. Fish-oil therapy in mucoviscidosis: A randomised double-blind study [abstract] [Fischol-Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde 1999;147(Suppl 2):107.
21. Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatric Pulmonology 1994;18(4):211-7.
22. Lloyd-Still J, Hoffman D, Arteburn L, Benisek D, Lester L. Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF [abstract]. Abstracts of the 24th European Cystic Fibrosis Conference. 2001:133.
23. Lloyd-Still J, Powers C, Hoffman D, Arterburn L, Benisek D, Lester L. Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis [abstract]. Pediatric Research 2001;49:455a.
24. Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al. A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):331.
25. Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study. Nutrition 2006;22(1):36-46.
26. Lloyd-Still J, Powers C, Hoffman D, Boyd-trull K, Arterburn L, Benisek D, et al. Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):263.
27. Romano L, Gandino M, Fiore P, Shepherd D, Casciaro R, Coccia C, et al. Study on feasibility and results of midterm dietary supplementation in omega-3 fatty acids [abstract]. Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167.
28. Starling MB, Elliot RB. EPA and cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress. 1988:74.
29. Van Biervliet S, Devos M, Delhaye J, Van Biervliet J, Robberecht E, Christophe A. Oral DHA supplementation in F508 homozygous cystic fibrosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 2008;78(2):109-15.
30. O'Sullivan B, Baker D, Borowitz D, Comeau A, Cleveland R, Freedman S. The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:401, Abstract no: 519. [CFGD Register: GN229; CRS-ID: 5500100000011193]
31. Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. American Journal of Human Nutrition 1998;67(5):912-8.
32. Littlewood J, Green M, Stannard W. Finding Out. CF Trust Factsheet 2006.
33. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD000407]
34. Corcoran AC, Rabinowitch IM. A study of the blood lipids and blood proteins in Canadian Eastern Arctic Eskimos. Biochemistry Journal 1937;31:343-8.
35. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology 1998;41(6):583-91.
36. Dodge JA. Nutritional requirement in cystic fibrosis: a review. Journal of Pediatric Gastroenterology Nutrition 1988;7(Suppl 1):S8-11.
37. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
38. Freedman SD, Alvarez JG. Pathogenesis of pancreatic disease in cystic fibrosis [abstract]. Pediatric Pulmonology 1999;Suppl 19:129.
39. Gaskin K, Gurwitz D, Durie P, Corey M, Levison H, Forstner G. Improved respiratory prognosis in patients with normal fat absorption. Journal of Pediatrics 1982;100(6):857-62.
40. Gazso A, Kaliman J, Horrobin DF, Sinzinger H. Effects of omega-3 fatty acids on the prostaglandin system in healthy probands. Wiener Klinische Wochenschrift 1989;101(8):283-8.
41. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
42. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. Hunt B, Geddes DM. Newly diagnosed cystic fibrosis in middle and later life. Thorax 1985;40(1):23-6.
44. Imrie J, Fagan D, Sturgess J. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and controlled subjects. American Journal Pathology 1975;95(3):697-708.
45. Jüni P, Douglas G, Altman G, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
46. Konstan MW. Treatment of airway inflammation in cystic fibrosis. Current Opinion in Pulmonary Medicine 1996;2(6):452-6.
47. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001505.pub2]
48. Lloyd-Still JD, Bibus DM, Powers CA, Johnson SB, Holman RT. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatrica 1996;85(12):1426-32.
49. Osterud B, Elvevoll E, Barstad H, Brox J, Halvorsen H, Lia K, et al. Effect of marine oils supplementation on coagulation and cellular activation in whole blood. Lipids 1995;30(12):1111-8.
50. Shwachman H, Kulczycki LL. Long term study of 105 patients with cystic fibrosis. American Journal of Diseases of Children 1958;96(1):6-10.
51. Wilmott RW, Khurana-Hershui G, Stark JM. Current concepts on pulmonary host defence mechanisms in children. Current Opinion in Pediatrics 2000;12(3):187-93.
52. Beckles-Willson NNR, Elliott T, Everard MML. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD002201.pub2]
53. Oliver C, Everard M, N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD002201.pub2]
54. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD002201.pub3]